Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.
Department of Geriatric Rehabilitation, Tel-Aviv Sourasky Medical Center, 64239, Tel Aviv, Israel.
Eur J Clin Microbiol Infect Dis. 2018 Jul;37(7):1281-1288. doi: 10.1007/s10096-018-3247-1. Epub 2018 Apr 7.
To estimate the rate and identified risk factors for recurrent Clostridium difficile infection (rCDI) in Israel. We conducted a retro-prospective case-control study of all adult (age ≥ 18 years) patients with an initial episode of CDI (iCDI) at Tel Aviv Sourasky Medical Center from January 1, 2012 to December 31, 2014. We collected demographic, clinical, and epidemiological information for patients who were classified as recurrent (cases) and non-recurrent (control) groups. In total, 648 patients with iCDI were identified in the study. During the 36-month study period, 82 (12.7%) patients had at least one rCDI identified. We identified several factors as independent variables significantly associated with recurrent CDI: functional disability, severity of the initial infection, continuous non-Clostridium difficile antibiotic treatment with third-generation cephalosporins or clindamycin, and iCDI treatment with metronidazole and vancomycin; however, neutropenia had high measure of effect as a predictor for rCDI (adjusted odds ratio, 7.9; 95% confidence interval, 1.27-49.58; p = 0.026). The identification of the main modifiable risk factors for recurrent CDI, continuous non-Clostridium difficile antibiotics after diagnosis of the initial infection, and antibiotic treatment with third-generation cephalosporins or clindamycin are critical in reducing the spread of recurrent infection with Clostridium difficile in hospital.
评估以色列复发性艰难梭菌感染(rCDI)的发生率和确定的危险因素。
我们对 2012 年 1 月 1 日至 2014 年 12 月 31 日期间在特拉维夫索拉斯基医学中心就诊的所有成人(年龄≥18 岁)初始艰难梭菌感染(iCDI)患者进行了回顾性病例对照研究。我们收集了患者的人口统计学、临床和流行病学信息,将其分为复发(病例)和非复发(对照)组。
在研究期间共发现 648 例 iCDI 患者。在 36 个月的研究期间,82 例(12.7%)患者至少发生了 1 次 rCDI。我们发现了几个与 rCDI 相关的独立因素:功能障碍、初始感染的严重程度、在诊断初始感染后持续使用非艰难梭菌抗生素(第三代头孢菌素或克林霉素)、使用甲硝唑和万古霉素治疗 iCDI;然而,中性粒细胞减少症作为 rCDI 的预测指标具有较高的效应量(调整后的优势比,7.9;95%置信区间,1.27-49.58;p=0.026)。
确定复发性 CDI 的主要可改变危险因素、在诊断初始感染后持续使用非艰难梭菌抗生素以及使用第三代头孢菌素或克林霉素进行抗生素治疗对于减少医院内艰难梭菌复发性感染的传播至关重要。